The Covovax shot developed by American vaccine-maker Novavax may be cleared for use in India between July and September, which would make it the fifth vaccine in the country. The vaccine would cost a "low single dollar" price per dose but is likely to be costlier than Covishield, the company's CEO said today in an exclusive interview. Stanley Erck, the president and CEO of Novavax, also said that while Covovax is known to work on Covid variants, the data of its effectiveness against the Delta variant is not known yet.
